research grant

The new, multinational iReceptor Plus Consortium will develop a platform for sharing of AIRR-seq data to advance immunotherapy and precision medicine.

The funds will provide financial support to the genome center's data and information technology unit beginning next year.

The company will partner with University College Dublin's Animal Genomics Laboratory to further develop genomic technologies to assess the origin, quality, and safety of food.

The partners will develop technology to predict the outcome of an NK-cell-based immunotherapy in patients with incurable locally advanced or metastatic solid tumors.

For the two five year grants, the NIH will favor applicants with experience providing counseling throughout the US and to diverse and disadvantaged communities.  

Led by investigators at the University of Trento in Italy, the team received a five-year, £5 million ($6.4 million) award recently to advance its work.

Over the next four years, researchers will aim to pinpoint the impact of personal genomic information given to patients with autism and their families.

IQuity develops tests that use RNA expression data to predict, detect, and monitor disease, as well as stratify patients by severity of disease.

The grants include funding for five new clinical sites, a new metabolomics core, and increased model organism capabilities.

Investigators are studying samples from a group of 100 patients to try to lock down patterns in circulating tumor DNA that can be used to validate monitoring methods for the clinic.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.